V-01D-351

V-01D-351 is a bivalent recombinant protein subunit COVID-19 vaccine booster developed as an updated formulation of the original V-01 vaccine. It contains receptor-binding domain (RBD) proteins from both the Beta (K417N, E484K, N501Y mutations) and Delta (L452R, T478K mutations) variants of SARS-CoV-2 in a 1:1 mixture. The vaccine is designed to enhance cross-neutralizing antibody responses against multiple SARS-CoV-2 variants of concern, including prototype, Delta, and Omicron strains. Clinical studies have shown that V-01D-351 induces robust and durable neutralizing antibody titers superior to those achieved with monovalent boosters or inactivated vaccines such as CoronaVac. The safety profile has been favorable with mostly mild or moderate adverse reactions[1][2][3][5][6].

Other names

V-01 bivalent vaccineV01 bivalent vaccineV 01 bivalent vaccineV-01 bivalent SARS-CoV-2 vaccineV01 bivalent SARS-CoV-2 vaccineV 01 bivalent SARS-CoV-2 vaccineV-01-351/V-01D bivalence vaccinerecombinant SARS-CoV-2 fusion protein bivalent vaccine